Adem Y Dawed,Andrea Mari,Andrew Brown,Timothy J McDonald,Lin Li,Shuaicheng Wang,Mun-Gwan Hong,Sapna Sharma,Neil R Robertson,Anubha Mahajan,Xuan Wang,Mark Walker,Stephen Gough,Leen M ‘t Hart,Kaixin Zhou,Ian Forgie,Hartmut Ruetten,Imre Pavo,Pallav Bhatnagar,Angus G Jones,Ewan R Pearson,L.M. 't Hart,M. Abdalla,J. Adam,J. Adamski,K. Adragni,K.H. Allin,M. Arumugam,N. Atabaki Pasdar,T. Baltauss,K.B. Banasik,P. Baum,J.D. Bell,M. Bergstrom,J.W. Beulens,S. Bianzano,R. Bizzotto,A. Bonneford,C.A.B. Brorsson,A.A. Brown,S.B. Brunak,L. Cabrelli,R. Caiazzo,M. Canouil,M. Dale,D. Davtian,A.Y. Dawed,F.M. De Masi,N. de Preville,K.F. Dekkers,E.T. Dermitzakis,H.A. Deshmukh,C. Dings,L. Donnelly,A. Dutta,B. Ehrhardt,P.J.M. Elders,C.E.T. Engel Thomas,L. Engelbrechtsen,R.G. Eriksen,R.E. Eriksen,Y. Fan,J. Fernandez,J. Ferrer,H. Fitipaldi,I.M. Forgie,A. Forman,P.W. Franks,F. Frau,A. Fritsche,P. Froguel,G. Frost,J. Gassenhuber,G.N. Giordano,T. Giorgino,S. Gough,U. Graefe-Mody,H. Grallert,R. Grempler,L. Groeneveld,L. Groop,V.G. Gudmundsdóttir,R.G. Gupta,M. Haid,T. Hansen,T.H. Hansen,A.T. Hattersley,R.S. Haussler,A.J. Heggie,A.M. Hennige,A.V. Hill,R.W. Holl,M.-G. Hong,M. Hudson,B. Jablonka,C. Jennison,J. Jiao,J.J. Johansen,A.G. Jones,A. Jonsson,T.K. Karaderi,J. Kaye,M. Klintenberg,R.W. Koivula,T. Kokkola,A.D.M. Koopman,A Kurbasic,T. Kuulasmaa,M. Laakso,T. Lehr,H. Loftus,R.L.A Lundbye Allesøe,A. Mahajan,A. Mari,G.M. Mazzoni,M.I. McCarthy,T.J. McDonald,D. McEvoy,N. McRobert,I. McVittie,M. Mourby,P. Musholt,P Mutie,R. Nice,C. Nicolay,A.M.N. Nielsen,B.N. Nilsson,C.N. Palmer,F. Pattou,I. Pavo,E.R. Pearson,O. Pedersen,H.K.P. Pedersen,M.H. Perry,H. Pomares-Millan,A. Ramisch,S.R. Rasmussen,V. Raverdi,M. Ridderstrale,N. Robertson,R.C. Roderick,M. Rodriquez,H. Ruetten,F. Rutters,W. Sackett,N. Scherer,J.M. Schwenk,N. Shah,S. Sharma,I. Sihinevich,N.B. Sondertoft,H. Staerfeldt,B. Steckel-Hamann,H. Teare,M.K. Thomas,E.L. Thomas,H.S. Thomsen,B. Thorand,C.E. Thorne,J. Tillner,A.T.L. Troen Lundgaard,M. Troll,K.D.T. Tsirigos,A. Tura,M. Uhlen,N. van Leeuwen,S. van Oort,H. Verkindt,H. Vestergaard,A. Viñuela,J.K Vogt,P.W.S Wad Sackett,D. Wake,M. Walker,A. Wesolowska-Andersen,B. Whitcher,M.W. White,H. Wu

Abstract:BACKGROUND: In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacogenomic studies of this inter-individual variation can provide both biological insight into drug action and provide biomarkers to inform clinical decision making. We therefore aimed to identify genetic variants associated with glycaemic response to GLP-1 receptor agonist treatment.METHODS: In this genome-wide analysis we included adults (aged ≥18 years) with type 2 diabetes treated with GLP-1 receptor agonists with baseline HbA1c of 7% or more (53 mmol/mol) from four prospective observational cohorts (DIRECT, PRIBA, PROMASTER, and GoDARTS) and two randomised clinical trials (HARMONY phase 3 and AWARD). The primary endpoint was HbA1c reduction at 6 months after starting GLP-1 receptor agonists. We evaluated variants in GLP1R, then did a genome-wide association study and gene-based burden tests.FINDINGS: 4571 adults were included in our analysis, of these, 3339 (73%) were White European, 449 (10%) Hispanic, 312 (7%) American Indian or Alaskan Native, and 471 (10%) were other, and around 2140 (47%) of the participants were women. Variation in HbA1c reduction with GLP-1 receptor agonists treatment was associated with rs6923761G→A (Gly168Ser) in the GLP1R (0·08% [95% CI 0·04-0·12] or 0·9 mmol/mol lower reduction in HbA1c per serine, p=6·0 × 10-5) and low frequency variants in ARRB1 (optimal sequence kernel association test p=6·7 × 10-8), largely driven by rs140226575G→A (Thr370Met; 0·25% [SE 0·06] or 2·7 mmol/mol [SE 0·7] greater HbA1c reduction per methionine, p=5·2 × 10-6). A similar effect size for the ARRB1 Thr370Met was seen in Hispanic and American Indian or Alaska Native populations who have a higher frequency of this variant (6-11%) than in White European populations. Combining these two genes identified 4% of the population who had a 30% greater reduction in HbA1c than the 9% of the population with the worse response.INTERPRETATION: This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists.FUNDING: Innovative Medicines Initiative and the Wellcome Trust.

Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study

The association of cardiometabolic, diet and lifestyle parameters with plasma glucagon-like peptide-1: An IMI DIRECT study

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease

Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls

Glucagon Receptor Signaling and Lipid Metabolism

Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease

Elevations in plasma glucagon are associated with reduced insulin clearance after ingestion of a mixed-macronutrient meal in people with and without type 2 diabetes

Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Dietary Protein Defends Lean Mass and Maintains the Metabolic Benefits of Glucagon Receptor Agonism in Mice

Alterations in Glucagon Levels and the Glucagon-to-Insulin Ratio in Response to High Dietary Fat or Protein Intake in Healthy Lean Adult Twins: A Post Hoc Analysis

Genetic Evidence for GLP‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH

Glucagon, Metabolic Dysfunction-Associated Steatotic Liver Disease and Amino Acids in Humans and Animals without Diabetes Mellitus—An Evidence Map

Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Glucagon kinetics assessed by mathematical modelling during oral glucose administration in people spanning from normal glucose tolerance to type 2 diabetes